Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PET Community And FDA Move Forward In Inspection, Drug Application Talks

This article was originally published in The Gray Sheet

Executive Summary

Final regulations governing the manufacture of radiopharmaceutical chemicals for use with positron emission tomography will not be in place by the November 1999 deadline mandated by the FDA Modernization Act, according to officials from FDA's Center for Drug Evaluation and Research.

You may also be interested in...



PET Drugs cGMP Proposed Rule, Guidance To Be Refined By CDER

FDA plans to clarify the quality control section of its preliminary draft proposed rule and proposed guidance for positron emission tomography (PET) radiopharmaceutical current good manufacturing practices

PET Drugs cGMP Proposed Rule, Guidance To Be Refined By CDER

FDA plans to clarify the quality control section of its preliminary draft proposed rule and proposed guidance for positron emission tomography (PET) radiopharmaceutical current good manufacturing practices

FDA Panel Tables Recommendation On O-15 Imaging Agent, Okays F-18, N-13

Additional information is needed to support FDA approval of water O-15 injection as an imaging agent to measure cerebral blood flow in patients with cerebral vascular disorders, FDA's Medical Imaging Drugs Advisory Committee concluded June 29.

Related Content

UsernamePublicRestriction

Register

MT011405

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel